This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Zacks Investment Ideas feature highlights: Meta Platforms, AT&T, BITB, IWM and Viking Therapeutics
by Zacks Equity Research
Meta Platforms, AT&T, BITB, IWM and Viking Therapeutics are part of the Zacks Investment Ideas article.
TNegative Net Change IWMPositive Net Change VKTXPositive Net Change METAPositive Net Change BITBPositive Net Change
biotechs computers cryptocurrency etfs internet-content
5 Small Drug Stocks to Buy From a Rebounding Industry
by Kinjel Shah
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
UTHRPositive Net Change ESPRPositive Net Change ALDXPositive Net Change HRTXPositive Net Change LYRAPositive Net Change
biotechs pharmaceuticals
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
VRTXNegative Net Change ACETPositive Net Change EDITPositive Net Change AKROPositive Net Change
biotechnology biotechs cell-therapy crispr earnings gene-editing gene-therapy medical pharmaceuticals
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
by Zacks Equity Research
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.
PBYIPositive Net Change VNDAPositive Net Change ACADPositive Net Change INDVPositive Net Change
biotechs earnings
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
PBYIPositive Net Change VNDAPositive Net Change APLSPositive Net Change INDVPositive Net Change
biotechs earnings
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
SNYPositive Net Change BIIBPositive Net Change PBYIPositive Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.
MRKNegative Net Change LGNDPositive Net Change ALDXPositive Net Change VRNAPositive Net Change
biotechs earnings medical
Beyond the "Mag 7": 3 Risk-On Market Forces
by Andrew Rocco
The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that the market is broadening quickly.
TNegative Net Change NVDAPositive Net Change IWMPositive Net Change VKTXPositive Net Change METAPositive Net Change BITBPositive Net Change
biotechnology biotechs bitcoin investing magnificent-7
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change RCKTNegative Net Change
biotechs earnings medical
CytomX (CTMX) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on CytomX Therapeutics' (CTMX) updates on key cancer immunotherapeutic candidates, CX-904 and BMS-986288, on the fourth-quarter 2023 earnings call.
BMYPositive Net Change AMGNPositive Net Change SRPTPositive Net Change CTMXPositive Net Change
biotechs
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
SRPTPositive Net Change CGENPositive Net Change PBYIPositive Net Change CGEMNo Net Change
biotechs
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
ACETPositive Net Change PBYIPositive Net Change FATEPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
CLDXNegative Net Change ESPRPositive Net Change DERMPositive Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.
AZNPositive Net Change MRKNegative Net Change SRPTPositive Net Change FUSNPositive Net Change
biotechs
Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.
SRPTPositive Net Change CGENPositive Net Change ARQTPositive Net Change DNAPositive Net Change
biotechs
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
SRPTPositive Net Change CGENPositive Net Change ETONPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
by Nalak Das
We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.
CEGPositive Net Change IPARNegative Net Change HEIPositive Net Change APLSPositive Net Change PCVXNegative Net Change
aerospace alt-energy biotechs consumer-staples
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.
CLDXNegative Net Change ESPRPositive Net Change APLSPositive Net Change VTRSNegative Net Change
biotechs earnings pharmaceuticals
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.
PBYIPositive Net Change ADMAPositive Net Change EDITPositive Net Change BHCNegative Net Change
biotechnology biotechs earnings pharmaceuticals
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.
SNYPositive Net Change BMRNNegative Net Change ACETPositive Net Change PBYIPositive Net Change
biotechs earnings gene-therapy medical
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.
REGNPositive Net Change PBYIPositive Net Change VNDAPositive Net Change NTLANegative Net Change
biotechs earnings
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
by Zacks Equity Research
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
BMYPositive Net Change PBYIPositive Net Change VNDAPositive Net Change
biotechs earnings
Why Apellis (APLS) Might Surprise This Earnings Season
by Zacks Equity Research
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
APLSPositive Net Change
biotechnology biotechs medical
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals